Chalcones Display Anti-NLRP3 Inflammasome Activity in Macrophages through Inhibition of Both Priming and Activation Steps-Structure-Activity-Relationship and Mechanism Studies.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
16 Dec 2020
Historique:
received: 06 10 2020
revised: 11 12 2020
accepted: 13 12 2020
entrez: 19 12 2020
pubmed: 20 12 2020
medline: 3 9 2021
Statut: epublish

Résumé

Chalcones are responsible for biological activity throughout fruits, vegetables, and medicinal plants in preventing and treating a variety of inflammation-related diseases. However, their structure-activity relationship (SAR) in inhibiting inflammasome activation has not been explored. We synthesized numerous chalcones and determined their SAR on lipopolysaccharide (LPS)-primed ATP-induced NLRP3 inflammasome activation. 11Cha1 displayed good inhibitory activity on release reaction of caspase-1, IL-1β, and IL-18. It significantly inhibited LPS-induced phosphorylation and proteolytic degradation of IĸB-α and nuclear translocation of NF-ĸB, but had little effect on mitogen-activated protein kinases (MAPKs) activities. Furthermore, 11Cha1 blocked LPS-induced up-regulation of NLRP3, pro-caspase-1, ASC, IL-18, and IL-1β, indicating the suppression on priming step of inflammasome activation. ASC dimerization and oligomerization are considered to be direct evidence for inflammasome activation. 11Cha1 profoundly inhibited ATP-induced formation of ASC dimers, trimers, and oligomers, and the assembly of ASC, pro-caspase-1, and NLRP3 in inflammasome formation. Decrease of intracellular K

Identifiants

pubmed: 33339319
pii: molecules25245960
doi: 10.3390/molecules25245960
pmc: PMC7767297
pii:
doi:

Substances chimiques

Chalcones 0
Inflammasomes 0
Interleukin-1beta 0
Lipopolysaccharides 0
NF-kappa B 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
NF-KappaB Inhibitor alpha 139874-52-5
Adenosine Triphosphate 8L70Q75FXE
Caspase 1 EC 3.4.22.36

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 107-2320-B-002-018-MY3 and MOST 106-2320-B-002 -005 -MY3

Références

Front Pharmacol. 2018 Oct 02;9:1123
pubmed: 30333752
Cell Death Dis. 2019 Feb 12;10(2):128
pubmed: 30755589
J Immunol. 2009 Jul 15;183(2):792-6
pubmed: 19542372
Immunity. 2013 Jun 27;38(6):1142-53
pubmed: 23809161
J Immunol. 2014 Apr 15;192(8):3881-8
pubmed: 24623131
J Leukoc Biol. 2014 Dec;96(6):1087-100
pubmed: 25210146
Molecules. 2020 Feb 28;25(5):
pubmed: 32121151
Adv Exp Med Biol. 2019;1172:143-155
pubmed: 31628655
J Immunol. 2009 Jul 15;183(2):787-91
pubmed: 19570822
Food Funct. 2019 Jan 22;10(1):422-431
pubmed: 30604787
Front Immunol. 2019 Feb 28;10:276
pubmed: 30873162
Int J Mol Sci. 2019 Jan 14;20(2):
pubmed: 30646518
Blood. 2010 Jul 1;115(26):5398-400
pubmed: 20407038
Cell Death Dis. 2019 Apr 5;10(4):313
pubmed: 30952839
Trends Mol Med. 2007 Nov;13(11):460-9
pubmed: 18029230
Front Pharmacol. 2019 May 28;10:573
pubmed: 31191313
Int J Mol Sci. 2019 Jun 13;20(12):
pubmed: 31200447
Int J Mol Sci. 2019 Dec 10;20(24):
pubmed: 31835548
Immunity. 2016 Oct 18;45(4):761-773
pubmed: 27692612
Int Immunopharmacol. 2020 Jul;84:106498
pubmed: 32304996
Alcohol Clin Exp Res. 2019 Aug;43(8):1662-1671
pubmed: 31162673
Antioxid Redox Signal. 2015 May 1;22(13):1111-29
pubmed: 25330206
J Exp Med. 2018 May 7;215(5):1315-1325
pubmed: 29549113
Trends Immunol. 2019 Nov;40(11):1035-1052
pubmed: 31662274
Front Immunol. 2018 Oct 08;9:2305
pubmed: 30349539
Curr Pharm Des. 2018;24(14):1449-1484
pubmed: 29589535
Trends Biochem Sci. 2016 Dec;41(12):1012-1021
pubmed: 27669650
Front Oncol. 2019 Nov 12;9:1220
pubmed: 31781509
Br J Dermatol. 2014 Apr;170(4):816-23
pubmed: 24734946
Bioorg Chem. 2020 May;98:103748
pubmed: 32179281
Mol Neurobiol. 2018 Feb;55(2):1082-1096
pubmed: 28092085
Exp Neurobiol. 2014 Jun;23(2):163-8
pubmed: 24963281
Front Pharmacol. 2020 Apr 22;11:483
pubmed: 32390839
J Immunol. 2011 Jul 15;187(2):613-7
pubmed: 21677136
Med Chem Res. 2015 Apr;24(4):1672-1680
pubmed: 25866456
Annu Rev Immunol. 2011;29:707-35
pubmed: 21219188
Cardiovasc Res. 2010 May 1;86(2):211-8
pubmed: 20202975
Science. 2010 Jan 15;327(5963):296-300
pubmed: 20075245
J Nutr Sci. 2016 Dec 29;5:e47
pubmed: 28620474
Phytother Res. 2018 Dec;32(12):2551-2559
pubmed: 30281174
Front Pharmacol. 2020 Jan 31;10:1626
pubmed: 32082152
Mol Cell. 2017 Oct 5;68(1):185-197.e6
pubmed: 28943315
Int J Mol Sci. 2019 Jul 06;20(13):
pubmed: 31284572
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Nature. 2016 Feb 18;530(7590):354-7
pubmed: 26814970

Auteurs

Wohn-Jenn Leu (WJ)

School of Pharmacy, College of Medicine, National Taiwan University, No. 33, Linsen S. Rd, Taipei 100, Taiwan.

Jung-Chun Chu (JC)

Graduate Institute of Pharmacognosy, Taipei Medical University, No. 250, Wuxing St., Taipei 110, Taiwan.

Jui-Ling Hsu (JL)

School of Pharmacy, College of Medicine, National Taiwan University, No. 33, Linsen S. Rd, Taipei 100, Taiwan.
Department of Pharmacy, New Taipei Municipal TuCheng Hospital, Chang Gung Memorial Hospital, New Taipei City 236, Taiwan.

Chi-Min Du (CM)

School of Pharmacy, College of Medicine, National Taiwan University, No. 33, Linsen S. Rd, Taipei 100, Taiwan.

Yi-Huei Jiang (YH)

School of Pharmacy, College of Medicine, National Taiwan University, No. 33, Linsen S. Rd, Taipei 100, Taiwan.

Lih-Ching Hsu (LC)

School of Pharmacy, College of Medicine, National Taiwan University, No. 33, Linsen S. Rd, Taipei 100, Taiwan.

Wei-Jan Huang (WJ)

Graduate Institute of Pharmacognosy, Taipei Medical University, No. 250, Wuxing St., Taipei 110, Taiwan.

Jih-Hwa Guh (JH)

School of Pharmacy, College of Medicine, National Taiwan University, No. 33, Linsen S. Rd, Taipei 100, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH